NCT01834651View on ClinicalTrials.gov

A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

July 18, 2016

Study Completion Date

July 18, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Cabozantinib

Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Edwin Posadas, MD

OTHER

NCT01834651 - A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases | Biotech Hunter | Biotech Hunter